| Literature DB >> 31326460 |
Lauren Kosten1, Golam M I Chowdhury2, Susana Mingote3, Steven Staelens1, Douglas L Rothman4, Kevin L Behar5, Stephen Rayport6.
Abstract
Glutaminase mediates the recycling of neurotransmitter glutamate, supporting most excitatory neurotransmission in the mammalian central nervous system. A constitutive heterozygous reduction in GLS1 engenders in mice a model of schizophrenia resilience and associated increases in Gln, reductions in Glu and activity-dependent attenuation of excitatory synaptic transmission. Hippocampal brain slices from GLS1 heterozygous mice metabolize less Gln to Glu. Whether glutaminase activity is diminished in the intact brain in GLS1 heterozygous mice has not been assessed, nor the regional impact. Moreover, it is not known whether pharmacological inhibition would mimic the genetic reduction. We addressed this using magnetic resonance spectroscopy to assess amino acid content and 13C-acetate loading to assess glutaminase activity, in multiple brain regions. Glutaminase activity was reduced significantly in the hippocampus of GLS1 heterozygous mice, while acute treatment with the putative glutaminase inhibitor ebselen did not impact glutaminase activity, but did significantly increase GABA. This approach identifies a molecular imaging strategy for testing target engagement by comparing genetic and pharmacological inhibition, across brain regions.Entities:
Keywords: Focused beam microwave irradiation; GABA; Glutamate-glutamine cycling; Magnetic resonance spectroscopy; Schizophrenia pharmacotherapy
Mesh:
Substances:
Year: 2019 PMID: 31326460 PMCID: PMC6941670 DOI: 10.1016/j.neuint.2019.104508
Source DB: PubMed Journal: Neurochem Int ISSN: 0197-0186 Impact factor: 3.921